| Literature DB >> 26175412 |
Sander Kelderman1, Ton N Schumacher1, Pia Kvistborg2.
Abstract
Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of sensing the consequences of DNA damage in cancer immunotherapy.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26175412 DOI： 10.1016/j.ccell.2015.06.012
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743